Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 6, 2026, 11:45 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 11,177 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Cohort study Clear all

Conditions: Acute Myeloid Leukemia
Interventions: combination therapy using decitabine and midostaurin; Drug
Lead sponsor: University of Kansas; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Advanced Solid Tumor, High Grade Serous Adenocarcinoma of Ovary, Squamous Non-small-cell Lung Cancer, Triple Negative Breast Cancer, Head and Neck Squamous Cell Carcinoma, Ovarian Carcinosarcoma, Uterine Carcinosarcoma, Uterine Serous Carcinoma, Endometrium Cancer, Chromosomal Instability
Interventions: VLS-1488; Drug
Lead sponsor: Volastra Therapeutics, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2026
U.S. locations: 14
States / cities: Los Angeles, California • Newport Beach, California • Aurora, Colorado + 11 more

Conditions: Knee Osteoarthritis
Interventions: TPX-100 50mg, TPX-100 100mg, TPX-100 200mg, TPX-100 20mg, Placebo; Drug
Lead sponsor: OrthoTrophix, Inc; Industry
Eligibility: 25 Years to 75 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2016
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Vaginal Stricture, Vaginal Stenosis
Interventions: UCSD Vaginal Dilator Questionnaire, EORTC Sexual Health Questionnaire; Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: La Jolla, California

Conditions: PML, AIDS
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: Not listed
Enrollment: 450 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2005
U.S. locations: 6
States / cities: Los Angeles, California • Chicago, Illinois • Baltimore, Maryland + 1 more

Conditions: Endometrial Cancer
Interventions: Hypofractionated Radiation, Clinical Follow-Up and Assessments; Radiation · Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Female only
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2026
U.S. locations: 5
States / cities: Atlanta, Georgia • Chicago, Illinois • Houston, Texas + 1 more

Conditions: Cancer, Breast Cancer, Ovarian Cancer
Interventions: Blood Collection, Patient Questionnaires; Other
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older · Female only
Enrollment: 43 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2027
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Infection Abdominal
Interventions: Abthera, Open adbdomen for post-laparotomy without NPWT device; Device · Procedure
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Recurrent Thyroid Gland Carcinoma, Stage III Differentiated Thyroid Gland Carcinoma AJCC v7, Stage III Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVA Differentiated Thyroid Gland Carcinoma AJCC v7, Stage IVA Thyroid Gland Anaplastic Carcinoma AJCC v7, Stage IVA Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVB Differentiated Thyroid Gland Carcinoma AJCC v7, Stage IVB Thyroid Gland Anaplastic Carcinoma AJCC v7, Stage IVB Thyroid Gland Medullary Carcinoma AJCC v7, Stage IVC Differentiated Thyroid Gland Carcinoma AJCC v7, Stage IVC Thyroid Gland Anaplastic Carcinoma AJCC v7, Stage IVC Thyroid Gland Medullary Carcinoma AJCC v7, Thyroid Gland Anaplastic Carcinoma
Interventions: Laboratory Biomarker Analysis, Pazopanib Hydrochloride; Other · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 19 Years and older
Enrollment: 152 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2019
U.S. locations: 16
States / cities: Scottsdale, Arizona • Aurora, Colorado • Jacksonville, Florida + 13 more

Conditions: Healthy, Sickle Cell Disease
Interventions: Not listed
Lead sponsor: Bioverativ Therapeutics Inc.; Industry
Eligibility: 18 Years to 45 Years
Enrollment: 38 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2016
U.S. locations: 1
States / cities: Detroit, Michigan

Conditions: Foot Ulcer, Diabetes Mellitus, Wound
Interventions: Wound debridement; Procedure
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years to 75 Years
Enrollment: 103 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Diastolic Heart Failure
Interventions: Meo Health Breathing and humming exercises; Behavioral
Lead sponsor: Lancaster General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 65 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Lancaster, Pennsylvania

Conditions: Mature B-Cell Malignancies
Interventions: Sonrotoclax, Zanubrutinib, Obinutuzumab; Drug
Lead sponsor: BeOne Medicines; Industry
Eligibility: 18 Years and older
Enrollment: 437 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2027
U.S. locations: 13
States / cities: Los Angeles, California • Chicago, Illinois • Kansas City, Kansas + 9 more

Conditions: Cancer Malignancies
Interventions: melatonin, placebo; Drug
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: 18 Years and older
Enrollment: 911 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Advanced Solid Tumors
Interventions: SNS-314; Drug
Lead sponsor: Sunesis Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 4
States / cities: Birmingham, Alabama • Stanford, California • Albuquerque, New Mexico + 1 more

Conditions: Thyroid Eye Disease (TED), Graves' Disease, Eye Diseases, Hereditary, Eye Diseases, Exophthalmos, Orbital Diseases, Goiter, Thyroid Diseases, Endocrine System Diseases, Hyperthyroidism, Autoimmune Diseases, Immune System Diseases, Graves Ophthalmopathy, Proptosis
Interventions: ETHY-001, Placebo; Drug · Other
Lead sponsor: Ethyreal Bio, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 72 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2028
U.S. locations: 3
States / cities: Orland Park, Illinois • Las Vegas, Nevada • Wilmington, North Carolina

Conditions: Hepatic Impairment, Normal Hepatic Function
Interventions: Esketamine; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 24 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2017
U.S. locations: 1
States / cities: Knoxville, Tennessee

Conditions: Papillomavirus Infections
Interventions: 9vHPV vaccine; Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 9 Years to 26 Years
Enrollment: 700 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2029
U.S. locations: 14
States / cities: Daly City, California • Oakland, California • Roseville, California + 10 more

Conditions: Overweight, Diabetes Mellitus Type 2 in Obese
Interventions: P11187, Placebo; Drug
Lead sponsor: Piramal Enterprises Limited; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 96 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Miami, Florida

Conditions: Chronic Pain, Intractable Pain
Interventions: Commercially available Inceptiv™ neurostimulation systems; Device
Lead sponsor: Medtronic; Industry
Eligibility: 18 Years and older
Enrollment: 970 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2034
U.S. locations: 8
States / cities: Phoenix, Arizona • San Diego, California • Temecula, California + 5 more

Conditions: Diabetes, Type2 Diabetes, Diabetes Mellitus
Interventions: Not listed
Lead sponsor: Fred Hutchinson Cancer Center; Other
Eligibility: 50 Years to 85 Years
Enrollment: 2,269 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 18
States / cities: Los Angeles, California • Oakland, California • Palo Alto, California + 13 more

Conditions: Functional Constipation
Interventions: Linaclotide, Placebo; Drug
Lead sponsor: Allergan; Industry
Eligibility: 2 Years to 5 Years
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2021
U.S. locations: 18
States / cities: Birmingham, Alabama • Hot Springs, Arkansas • Little Rock, Arkansas + 15 more

Conditions: Non Small-cell Lung Cancer
Interventions: Liquid biopsy for aberrant DNA methylation analysis - Indeterminate pulmonary nodule, Liquid biopsy for aberrant DNA methylation analysis - Known lung cancer for surgical resection, Liquid biopsy for aberrant DNA methylation analysis - Healthy volunteer, Liquid biopsy for aberrant DNA methylation analysis - Benign lung disease; Diagnostic Test
Lead sponsor: University of Arizona; Other
Eligibility: 18 Years and older
Enrollment: 171 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Tucson, Arizona

Conditions: Healthy Participants
Interventions: INCB123667, itraconazole, carbamazepine; Drug
Lead sponsor: Incyte Corporation; Industry
Eligibility: 19 Years to 55 Years
Enrollment: 51 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Lincoln, Nebraska

Search by objective public record fields.

Combination of Decitabine and Midostaurin in Patients Older Than 60 With Newly Diagnosed or Relapsed Refractory Acute Myeloid Leukemia

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

A Study Evaluating the Safety and Efficacy of Intra-articular Injections of TPX-100 in Subjects With Mild to Moderate Patello-Femoral Osteoarthritis Involving Both Knees

Quantifying Radiation Induced Vaginal Stenosis

Genetics of Progressive Multifocal Leukoencephalopathy and Acquired Immunodeficiency Syndrome

Study of Pelvic Hypofractionated Radiotherapy in Endometrial Cancer

Assessment of Paclitaxel-Induced Neuropathy

Delayed Primary Closure Using Negative Pressure Wound Therapy

Pazopanib Hydrochloride in Treating Patients With Advanced Thyroid Cancer

Study of Methodologies to Measure Blood Flow and Oxygenation in Adults With Sickle Cell Disease

Diabetic Foot Ulcers Microbiome and Pathogen Identification

Parasympathetic Augmentation Via Respiratory Training for Patients With Systolic Heart Failure

Study of Bcl-2 Inhibitor Sonrotoclax (BGB-11417) in Participants With Mature B-Cell Malignancies

Melatonin Intervention For Neurocognitive Deficits in the St. Jude Lifetime Cohort

Safety and Tolerability Study of SNS-314 for Advanced Solid Tumors

Evaluation of ETHY-001 for Safety, Tolerability, and Clinical Activity in Thyroid Eye Disease

A Study to Assess the Effects of Hepatic Impairment on the Pharmacokinetics, Safety, and Tolerability of Intranasally Administered Esketamine

Safety and Immunogenicity of Extended 2-dose Regimens of 9-valent Human Papillomavirus (9vHPV) Vaccine (V503-069)

Determination of Safety,Tolerability,Pharmacokinetics,Food Effect& Pharmacodynamics of Single & Multiple Doses of P11187

Post Market Evaluation of Real World Outcomes and Durability to Support Implantable Inceptiv™ Spinal Cord Stimulation Therapy

A Study to Establish a New Onset Hyperglycemia and Diabetes Cohort

Linaclotide Safety and Efficacy in 2 to 5-Year-Old Participants With Functional Constipation

Liquid Biopsy for Early Non-small Lung Cancer Detection

A Study to Evaluate the Effect of Food on the Single-Dose Pharmacokinetics and a Drug-Drug Interaction Evaluation of Itraconazole and Carbamazepine on INCB123667 When Administered Orally to Healthy Adult Participants